Congratulations to Precision’s Iver Jensen for his contributions to “Health Economics of Selective Early Rescue Surfactant Administration and Standard Surfactant Administration for Newborns With Respiratory Distress Syndrome,” a study recently published in the Journal of Pediatric Pharmacology and Therapeutics. The study is the first cost-consequence analysis cost-consequence analysis comparing the clinical and health economic outcomes in newborns with RDS when using selective early surfactant treatment vs standard surfactant administration in the United States. Read the study here:
